Clinical course of asymptomatic malignant pleural effusion in non-small cell lung cancer patients
نویسندگان
چکیده
منابع مشابه
Prognostic value of pleural effusion in patients with non-small cell lung cancer.
This study was performed to determine whether pleural effusion in patients with advanced non-small cell lung cancer (NSCLC) has a negative impact on survival. We evaluated 12 prognostic factors in 197 patients with stage IIIB or IV NSCLC. Each factor was dichotomized, and survival curves calculated by the Kaplan-Meier technique were compared using the log-rank test. The Cox proportional hazards...
متن کاملClinicopathological Features of Patients with Non-small-cell Lung Cancer in West of Iran
Background: Lung cancer is the most common cause of cancer death worldwide with an annual mortality rate of more than 1.3 million worldwide. We aimed to analyze the clinicopathological features of patients with non-small-cell lung cancer (NSCLC) in west of Iran. Methods: 64 patients with NSCLC who referred to our clinic were analyzed. Sex, age, histopathology, location of the tumor, treatment,...
متن کاملThe Role of Immunohistochemistry Studies in Distinguishing Malignant Mesothelioma from Metastatic Lung Carcinoma in Malignant Pleural Effusion
Background and Objective: Early diagnosis of malignant pleural mesothelioma (MPM) is the key point of its treatment. The main problem is the precise diagnosis of mesothelioma and its differentiation from metastatic lung adenocarcinoma. Mesothelioma exhibits complex immunohistochemical characteristics. The aim of this study was to study hybrid immunohistochemistry in the differe...
متن کاملSoluble CD40 in plasma and malignant pleural effusion with non-small cell lung cancer: A potential marker of prognosis
OBJECTIVE Soluble CD40 (sCD40) is a potential modulator for both antitumor responses and CD40-based immunotherapy; however the levels and significance of sCD40 in non-small cell lung cancer (NSCLC) patients with malignant pleural effusion are unknown. METHODS Forty-eight patients with lung cancer were treated in our institutions from January 2008 to January 2010. Peripheral blood and pleural ...
متن کاملIntrapleural combination therapy with bevacizumab and cisplatin for non-small cell lung cancer‑mediated malignant pleural effusion.
Malignant pleural effusion (MPE) is a common complication of advanced non-small cell lung cancer (NSCLC). Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), has been shown to be efficient in suppressing the accumulation of pleural fluid. However, whether intrapleural delivery of bevacizumab can be used to treat MPE remains unknown. The aim of the pre...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Medicine
سال: 2021
ISSN: 0025-7974,1536-5964
DOI: 10.1097/md.0000000000025748